HCW Biologics Inc. — Q1 2023 Form 10-Q
Business context and period. Clinical-stage biopharmaceutical company developing immunotherapies targeting chronic inflammation and age-related diseases. This unaudited report covers the three months ended March 31, 2023, compared with Q1 2022. The company has no commercial product sales; revenue to date has come from Wugen licensing and materials-supply arrangements.
Financial performance and position
- Revenue: $41,883, down from $3.12 million in Q1 2022. Management attributed the comparison mainly to recognition of deferred Wugen supply revenue in Q1 2022. Q1 2023 cost of revenue was $29,350, leaving net revenue of $12,533.
- Expenses and loss: Research and development expense rose 26% to $2.26 million; general and administrative expense rose 66% to $3.12 million, including $1.1 million of Altor/NantCell legal fees. Operating loss was $5.36 million versus $1.88 million; net loss was $5.07 million versus $2.06 million. Basic and diluted loss per share was $0.14 versus $0.06.
- Cash flow: Cash used in operating activities was $3.64 million, compared with $1.59 million used in Q1 2022. Capital spending was $300,385; ending cash and cash equivalents were $18.39 million.
- Liquidity and debt: At March 31, cash and cash equivalents were $18.39 million and short-term U.S. government-backed investments were $9.85 million. Current assets were $29.94 million and current liabilities $4.52 million. Gross Cogent Bank loan principal was $6.5 million (reported debt, net, $6.39 million), secured by the building and bearing 5.75% interest. Principal and interest payments were scheduled to begin September 2023. The company reported covenant compliance.
- Balance sheet: Total assets were $43.53 million, total liabilities $10.92 million, and stockholders’ equity $32.62 million at quarter-end.
Material changes, outlook and risks
- On April 21, 2023, after quarter-end, the company entered into a secured development line of credit with aggregate principal capacity of up to $26.25 million, a 7% fixed rate and scheduled maturity in April 2028. Management said it intended to use part of the proceeds from the first advance to repay the Cogent loan and finance the new headquarters and manufacturing-facility buildout.
- Management stated that March 31 cash and short-term investments were expected to fund operations for at least 12 months, while also noting that additional capital will be needed to fully implement its business plan. If adequate financing is unavailable, development plans may be delayed or revised.
- HCW9218 was being evaluated in two Phase 1/1b trials for solid tumors. Management expected a preliminary data readout and completion of the investigator-sponsored Phase 1 dose-escalation phase in the first half of 2023, and expected to complete the Phase 1b portion of the pancreatic-cancer study in 2023. HCW9302 remained preclinical; the company expected to submit an IND in 2023 and anticipated completing a toxicology study in the first half of 2023.
- Altor/NantCell’s claims against the company and its CEO moved to JAMS arbitration after the federal action was dismissed without prejudice in May 2023. The company said potential loss could not be reasonably estimated and recorded no accrual; it expected continued material legal-defense costs.
- Management cited supply-chain disruptions, inflation, rising interest rates, geopolitical uncertainty and COVID-related delays as factors that could increase costs or delay trials and IND-enabling work. It reported no exposure to a failed bank. Disclosure controls and procedures were assessed as effective, with no material change in internal control reported for the quarter.
Investor facts to verify
- Progress, enrollment and timing of HCW9218 trials, and whether the expected 2023 readouts and milestones were achieved.
- HCW9302 IND-enabling and submission timing, and any effects of manufacturing or supply constraints.
- Terms, availability and actual draws under the $26.25 million credit facility, including use of proceeds, repayment of the Cogent loan and resulting liquidity.
- Subsequent developments and potential financial impact of the Altor/NantCell arbitration, including legal costs.
- Cash burn, financing needs and the basis for management’s stated 12-month liquidity expectation.